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Abstract
Background: Staphylococcus aureus bacteremia is a common infection associated with significant morbidity
and mortality. Telavancin is a bactericidal lipoglycopeptide active against Gram-positive pathogens, including
methicillin-resistant S. aureus (MRSA). We conducted a randomized, double-blind, Phase 2 trial in patients with
uncomplicated S. aureus bacteremia.
Methods: Patients were randomized to either telavancin or standard therapy (vancomycin or anti-staphylococcal
penicillin) for 14 days. Continuation criteria were set to avoid complicated S. aureus bacteremia. The primary end
point was clinical cure at 84 days.
Results: In total, 60 patients were randomized and 58 received ≥1 study medication dose (all-treated), 31 patients
fulfilled inclusion/exclusion and continuation criteria (all-treated target [ATT]) (telavancin 15, standard therapy 16),
and 17 patients were clinically evaluable (CE) (telavancin 8, standard therapy 9). Mean age (ATT) was 60 years.
Intravenous catheters were the most common source of S. aureus bacteremia and ~50% of patients had MRSA. A
similar proportion of CE patients were cured in the telavancin (88%) and standard therapy (89%) groups. All patients
with MRSA bacteremia were cured and one patient with MSSA bacteremia failed study treatment in each group.
Although adverse events (AEs) were more common in the telavancin ATT group (90% vs. 72%), AEs leading to drug
discontinuation were similar (7%) in both treatment arms. Potentially clinically significant increases in serum creatinine
(≥1.5 mg/dl and at least 50% greater than baseline) were more common in the telavancin group (20% vs. 7%).
Conclusions: This study suggests that telavancin may have utility for treatment of uncomplicated S. aureus bacteremia;
additional studies are warranted. (Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia
(ASSURE); NCT00062647).
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Background
Staphylococcus aureus bacteremia (SAB) is a devastating
infection associated with high mortality, morbidity, and
medical costs [1-3]. Approximately 40% of patients with
SAB will have a complicated infection and more than 25%
of these patients will die within the 12 weeks following
their initial positive blood culture [2]. Bacteremia is
also a common form of invasive infection due to
methicillin-resistant S. aureus (MRSA) [4].
Vancomycin, the most commonly used antibiotic in
hospitalized patients with MRSA bacteremia, has several
limitations [5], including the rise of strains with decreased
susceptibility [6,7] or resistance [8,9] and suboptimal re-
sults for the treatment of patients with bacteremia due to
methicillin-susceptible S. aureus (MSSA) [10,11]. Despite
the dramatic consequences of SAB and the limitations of
vancomycin, only one registrational, open-label, random-
ized clinical trial in patients with SAB has been conducted
[12], and vancomycin remains first-line therapy for MRSA
bacteremia in most settings [13].
Telavancin is a lipoglycopeptide antibacterial agent
exhibiting concentration-dependent bactericidal effects
via a dual mechanism of action that combines inhibition
of cell wall synthesis and disruption of membrane
barrier function [14-16]. Telavancin has been approved in
the U.S. and Canada for the treatment of patients
with complicated skin and skin structure infections
due to Gram-positive pathogens, and in Europe for
the treatment of hospital-acquired pneumonia (including
ventilator-associated pneumonia) due to MRSA, when
alternative medicines are unsuitablea. Most recently
(June 2013), telavancin was approved in the U.S. for
hospital-acquired and ventilator-associated bacterial
pneumonia caused by susceptible isolates of S. aureus
when alternative treatments are not suitable. In vitro,
telavancin is bactericidal against clinically important
Gram-positive bacteria, including MSSA, MRSA,
vancomycin intermediate susceptible (VISA) [17], and
hetero-intermediate strains (hVISA) [18]. Animal models
of infection suggested that telavancin may be an effective
treatment for SAB and endocarditis [17,19,20]. However,
clinical experience in patients with SAB or endocarditis
due to S. aureus treated with telavancin is limited [21,22].
The ASSURE study (Telavancin for Treatment of
Uncomplicated S. aureus Bacteremia) was conducted as a
proof-of-concept study for telavancin compared with
standard therapy for the treatment of uncomplicated SAB.
Methods
This proof-of-concept study was a Phase 2, randomized,
double-blind, active-controlled, parallel group, multinational
trial (NCT00062647), conducted from August 2003 through
August 2006. Studies were approved by each institutional
review board or ethics committee (see Additional file 1),
and written informed consent was obtained from all
patients or their legal representatives. Patients were
randomized through an interactive voice response system
in a 1:1 ratio, using a permuted block algorithm. The
randomization was stratified by geographic region (within
or outside the U.S.).
Study population and continuation criteria
Patients were considered for the study if they were ≥18 years
of age and had uncomplicated S. aureus bacteremia (with a
qualifying blood culture [QBC]). Patients were excluded if
they had any of the following: non-removable hardware
(e.g., vascular stents or grafts placed within the last
6 weeks, joint prosthesis, or cardiovascular devices),
removable source of infection (e.g., central catheter)
that was not planned to be removed within 24 h from the
QBC, significant cardiac valvular disease, any intra-cardiac
mass or abscess defined by transthoracic or transesophageal
echocardiography, prior history of endocarditis or osteo-
myelitis, recent infection with S. aureus requiring systemic
antibacterial therapy within the last 30 days, evidence of
metastatic complication (e.g., deep abscesses, endocarditis,
osteomyelitis), or signs of vascular phenomena indicating
potential arterial embolism (e.g., brain hemorrhage,
pulmonary infarcts, Janeway lesions). Patients were also ex-
cluded if they had QTc (Fredericia’s corrected) >470 msec,
uncompensated heart failure or unstable angina within the
last 30 days, abnormal serum levels of potassium or magne-
sium that could not be corrected, hypotension or oliguria
unresponsive to resuscitation with fluid or vasopres-
sors, recent systemic antimicrobial therapy potentially
effective against S. aureus (>72 h within the last 7 days),
neutrophil count <500 cells/mm3, HIV infection with
CD4 count <100 cells/mm3 during the last 6 months, ala-
nine aminotransferase or aspartate aminotransferase >5-
fold the upper limit of normal or with Child-Pugh class B
or C hepatic disease, immunosuppressant therapy, or
concomitant use of agents containing cyclodextrin.
After initiation of study drug, patients were continued
in the study only if they met all the following criteria: a)
patients with MRSA bacteremia had been receiving
vancomycin as initial therapy, b) removal of all removable
foci within 24 h after the report of the QBC, c) negative
follow-up blood cultures (FUBC) drawn 24 to 48 h after
the report of the QBC, d) resolution of fever (≤38.0°C)
within 72 h of the initiation of antistaphylococcal therapy, e)
pre-treatment urine culture negative for S. aureus, f) trans-
thoracic or transesophageal echocardiography, following
QBC, showing no significant valvular disease, and g) no evi-
dence of a metastatic complication on or before Day 5.
Antimicrobial therapy
Patients were randomized to either telavancin 10 mg/kg
intravenous (IV) q 24 h or standard therapy (vancomycin
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1 g IV q 12 h, or nafcillin 2 g IV q 6 h, oxacillin 2 g IV q
6 h, or cloxacillin 2 g IV q 6 h). An anti-staphylococcal
penicillin (ASP) could be selected if the baseline pathogen
was known or highly suspected to be MSSA. The total
duration of treatment with study medications was 14 days.
Dummy infusions were used to maintain the study
blinding and blinding of study medication was performed
in the pharmacy.
Vancomycin was dosed per the U.S. Food and Drug
Administration (FDA)-approved label. The dose of
vancomycin could be adjusted by local institutionally
accepted policies based on weight, serum levels, and/or
renal function. Any dosage adjustments or obtention of
serum levels of vancomycin were performed in a manner
that maintained the study blind, usually by a designated
pharmacist. Each site was to have submitted a blinding
plan that was approved by the study sponsor.
The dose of telavancin was adjusted in patients with
renal impairment: 7.5 mg/kg q 24 h and 10 mg/kg q
48 h for patients with creatinine clearance between 30 to
50 ml/min and <30 ml/min, respectively.
Vancomycin was continued in patients who were re-
ceiving vancomycin prior to randomization and were
randomized to standard therapy. If the organism subse-
quently proved to be MSSA, vancomycin could have
been changed to an ASP (nafcillin, oxacillin, or cloxacillin)
at the investigator’s discretion.
Assessments
Clinical assessments were conducted at baseline and
daily through to the end of therapy (EOT). EOT evaluation
was performed within 72 h after administration of the last
dose of study medication. A follow-up (FU) visit was sched-
uled 7 to14 days after EOT, and a test-of-cure (TOC) visit
was scheduled 84 days after the start of study medication.
At each evaluation, investigators assessed the signs,
symptoms, and extent of the infection, surgical procedures,
adverse events (AEs), and concomitant medications.
Two independent blood culture (BC) specimens were
obtained within 24 to 48 h after the report of the QBC,
EOT, and at the FU visit. Blood cultures were not obtained
at TOC or at other time points, unless clinically indicated.
All pathogens isolated were sent to a central microbiology
laboratory for identification of genus and species and MIC
testing.
Electrocardiograms were obtained in triplicate at baseline,
every third day, and at EOT evaluation. Laboratory tests
were performed at baseline, every 3 days during treatment,
and at EOTand FU visits.
Study outcomes
Clinical response assessed by the investigators at TOC was
the primary end point of the study. Cure was defined by all
the following criteria: resolution of clinical symptoms/signs
associated with the bacteremia, no evidence of metastatic
complications, all cultures negative for S. aureus after QBC
cultures, and no non-study systemic anti-staphylococcal
medication to which the baseline pathogen was susceptible.
Failure was defined by any of the following: presence of
symptoms/signs associated with the bacteremia, evidence
of metastatic complications, positive blood culture for S.
aureus, or death related to initial study infection after
study Day 3. Indeterminate was defined by the inability to
determine the outcomes mentioned above.
Analysis groups
The following groups were defined for the analysis: a)
all-treated (AT), patients who received ≥1 dose of
study medication, b) all-treated target (ATT) patients
who received study medication and fulfilled all inclusion/
exclusion and continuation criteria (or who were approved
for inclusion after careful review by the medical monitor
to determine that the patient could be appropriately
assessed), and c) clinically evaluable (CE), patients in the
ATT population who received 12 to 16 days of study
medication and whose study participation did not deviate
from the protocol by more than pre-specified limits.
The objective of this study was to assess safety, tolerabil-
ity, and explore efficacy (proof-of-concept). Sample
Table 1 Study visits and reasons for early discontinuation
of study medication
Telavancin Standard
therapy
Overall
(n = 29) (n = 29) (n = 58)
Completed FU visit 23 (79%) 26 (90%) 49 (84%)
Completed TOC visit 14 (48%) 17 (59%) 31 (53%)
Completed 14 days of therapy 13 (45%) 17 (59%) 30 (52%)
Discontinued study drugs early 16 (55%) a 12 (41%) 28 (48%)
Reason for early study drug
discontinuation
Continuation criteria not metb 5 (17%) 2 (7%) 7 (12%)
Adverse event 2 (7%) 2 (7%) 4 (7%)
Consent withdrawal 2 (7%) 2 (7%) 4 (7%)
2 Consecutive ECGs with
QTc >500 msec
0 1 (3%) 1 (2%)
Major protocol deviation 1 (3%) c 0 1 (2%)
Other 6 (21%) 5 (17%)d 11 (19%)
AE, adverse event; ECG, electrocardiogram; FU, follow-up visit; TOC,
test-of-cure visit.
aIncludes the only patient who was included under the amendment for
complicated bacteremia and who was discontinued due to an AE after
receiving 24 days of therapy.
bA patient may have failed more than one continuation criterion; in patients
failing continuation criteria the reason for early drug discontinuation decided
by the investigators may have been different from not meeting such
continuation criteria.
cThis patient also failed continuation criteria.
dOne patient in this group also failed continuation criteria.
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size (60 patients randomized) was selected on the basis of
clinical judgment in order to provide informative results
consistent with the study objective. This study was
not designed or powered to produce statistically significant
results. The difference between rates of response within
each treatment group was estimated with 95% confidence
interval (CI), calculated using the method of Agresti and
Caffo [23].
The protocol was amended to increase the daily dose
of telavancin to 12.5 mg/kg and to include patients
with complicated bacteremia, allowing 28 to 42 days
of therapy in such patients. However, following U.S.
FDA recommendations this amendment was rescinded
shortly after its implementation.
Results
A total of 60 patients were randomized in the study. Among
those, 58 patients from 21 sites in five countries received at
least one dose of study medication (AT population)
(Table 1). Patients were enrolled in the U.S., Argentina,
Spain, Singapore, and Hong Kong. Most patients were
enrolled in the U.S. (73%). Figure 1 displays the disposition
of patients into the study populations. Only one patient
was included under the amendment allowing complicated
bacteremia, received telavancin 10 mg/kg q 24 h for 24 days,
and was discontinued due to an AE.
A total of 55% of patients in the telavancin group
and 41% in the standard therapy group discontinued
the study drugs early. The most common reason for
early discontinuation of study drug due to continuation
criteria failure was the presence of positive FUBC. Among
telavancin-treated patients who discontinued the drug
early because of a positive FUBC result, four of five had
their FUBC obtained before starting telavancin. Study
visits and reasons for early study drug discontinuation are
displayed in Table 1.
Overall, demographics and clinical characteristics were
similar in the two groups (Table 2; ATT population).
Most patients were male, white, and the mean age
was 60 years. Diabetes was common in both treatment
Figure 1 Patient disposition into the study populations. More than one reason may be present for patients to be excluded from all-treated
target and/or clinically evaluable populations. SAB, S. aureus bacteremia; TOC, test of cure.
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groups. There were more obese patients in the telavancin
treatment group. The source of bacteremia was identified
in the vast majority of cases, with IV catheters being
the most common source in both groups. All IV
catheters identified as a source of infection were re-
moved within 24 h after the report of the qualifying
blood culture. The majority of patients in the telavancin
and standard therapy groups received prior systemic
antimicrobial therapy with vancomycin within 7 days
prior to initiation of study medication. MRSA was
isolated from the blood cultures of 47% and 50% of
the telavancin and standard therapy patient groups,
respectively.
All baseline isolates of S. aureus available for testing
were susceptible to vancomycin at a minimum inhibitory
concentration (MIC) of ≤1 μg/ml (n = 40; MIC90 = 1 μg/ml
for both MRSA and MSSA) and to telavancin at an MIC
of ≤0.5 μg/ml (n = 32; MIC90 = 0.5 μg/ml for both MRSA
and MSSA). Telavancin MICs for these isolates were tested
according to the Clinical Laboratory Standards Institute
(CLSI) guidelines in place at the time that this study
was performed and susceptibility was interpreted with
the corresponding FDA breakpoints approved in 2009.
The MIC testing methodology and corresponding
FDA-approved breakpoints for telavancin have recently
been revised and are published in the CLSI M100-S24
guidelines and telavancin product insert (March 2014),
respectively.
In the standard therapy group, seven of 16 patients
were treated with an ASP from the beginning and one
patient was switched from vancomycin to ASP on study
day 4 due to a blood culture being positive for MSSA on
day 3.
The CE population was limited to eight patients in the
telavancin and nine patients in the standard therapy
group. A similar proportion of patients were cured in
the telavancin (88%) and standard therapy (89%) treatment
groups (Table 3). All patients with MRSA bacteremia were
cured, and one patient with methicillin-resistant S. aureus
bacteremia failed study treatment in each treatment group
(Table 4). The patient who failed therapy in the tela-
vancin group was a 73-year-old female with a peripheral
catheter-related MSSA bacteremia whose blood cultures
were positive on study Day 28 and was subsequently
found to have osteomyelitis. The patient who failed
therapy in the standard therapy group was a 75-year-old
male with MSSA bacteremia from an unidentified
source who died after being readmitted on study Day
48 with an intestinal ischemia and positive blood cultures
for MSSA.
Among CE patients, microbiological eradication at
TOC was achieved in 88% of patients in the telavancin
group and 78% of patients in the standard therapy group.
The two patients who relapsed (one in each treatment
group) were considered clinical failures and have already
been described. In addition, one patient in the standard
therapy group who was considered clinically cured at
TOC had one of two BCs positive for MRSA. The most
relevant characteristics and outcomes of patients in the
CE population are described in Table 4.
Table 2 Clinical and demographic characteristics in the
all-treated target population
Telavancin Standard
therapy
Overall
(n = 15) (n = 16) (n = 31)
Age in years (mean ± SD) 59 ± 16.3 60 ± 20.4 60 ± 18.2
Age ≥65 5 (33%) 7 (44%) 12 (39%)
Gender, male 10 (67%) 8 (50%) 18 (58%)
Race, white 11 (73%) 10 (63%) 21 (68%)
Body mass index ≥30 6 (40%) 3 (19%) 9 (29%)
Diabetes 7 (47%) 10 (63%) 17 (55%)
Prior antimicrobial therapya 14 (93%) 16 (100%) 30 (97%)
Vancomycin 13 (87%) 14 (88%) 27 (87%)
Primary source of bacteremia
identified
12 (80%) 13 (81%) 25 (81%)
IV catheter 8 (53%) 9 (56%) 17 (55%)
Skin and soft tissue 3 (20%) 3 (19%) 6 (19%)
Other 1 (7%) 1 (6%) 2 (6%)
MRSA 7 (47%) 8 (50%) 15 (48%)
IV, intravenous; MRSA, methicillin-resistant Staphylococcus aureus.
aWithin 7 days prior to initiation of study medication.
Table 3 Cure rates and missing patients in the all-treated
target and clinically evaluable populations
Telavancin Standard
therapy
95% CI for
the difference
(telavancin–standard
therapy)
n/N (%) n/N (%)
All-treated target
End-of-
therapy visit
11/15
(73%)
15/16 (94%) (–44.4, 7.8)
Follow-up visit 9/15 (60%) 14/16 (88%) (–53.6, 4.5)
Test-of-cure
visit
8/15 (53%) 11/16 (69%) (–45.9, 18.5)
Clinically
evaluable
End-of-
therapy visit
8/8 (100%) 9/9 (100%) (–26.1, 24.3)
Follow-up visit 7/8 (88%) 9/9 (100%) (–41.0, 19.1)
Test-of-cure
visit
7/8 (88%) 8/9 (89%) (–35.5, 31.9)
MRSA 5/5 (100%) 4/4 (100%) -
MSSA 2/3 (67%) 4/5 (80%) -
CI, confidence interval; MRSA, methicillin-resistant Staphylococcus aureus; MSSA,
methicillin-susceptible Staphylococcus aureus.
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AEs and serious AEs (SAEs) were more common
in the telavancin group (Table 5), although only two
patients in each group discontinued the study medication
because of an AE. Overall types of AEs were similar in the
two study groups. Most common AEs included pyrexia,
headache, anemia, and rash. No individual SAE occurred
in more than one patient per treatment group. Five and
three patients died in the telavancin and standard therapy
groups (17% vs. 10%), respectively. Among patients who
died in the telavancin group, one patient withdrew con-
sent after the first dose and died from endocarditis, two
patients were discontinued early because of failure to meet
continuation criteria (one with endocarditis and one with
metastatic soft tissue abscess), and two patients died after
completing study medication (one with prostate cancer
and cardiorespiratory failure and one who the investigator
deemed to have [probable] sepsis from the urinary tract).
Among patients who died in the standard therapy
group, one patient died with MSSA bacteremia and
intestinal ischemia (described above), one patient developed
endocarditis, and one patient died from a neuroleptic
malignant syndrome. Potential clinically significant
increases in serum creatinine (serum creatinine ≥1.5 mg/dl
and at least 50% greater than baseline at any time point
through the EOT visit) were more common in telavancin-
treated patients (5/25 vs. 2/28). The rates of resolution
(completely or partially resolved) were two of five telavan-
cin patients and two of two vancomycin patients by the last
study visit. Otherwise, laboratory abnormalities were similar
between the study groups (Table 6).
Discussion
The ASSURE study is the first clinical trial evaluating
telavancin in the treatment of patients with uncomplicated
SAB. The study has provided several findings that should
be noted.
This study provides proof-of-concept for telavancin
in patients with uncomplicated SAB. Although cure
rates in ATT patients were numerically higher (not
statistically significant) in the standard therapy group,
a similar proportion of CE patients were cured in the
telavancin and standard therapy arm (88% vs. 89%)
(Table 3). One patient in the standard therapy group
who was considered cured had positive blood cultures
during the FU visit. Although this patient should have
been considered a clinical failure, the authors have
chosen to be conservative in this report and maintain
the original assessment. The only CE patient who
failed in the telavancin group was found to have
osteomyelitis several weeks after finishing therapy.
Table 4 Main characteristics, therapy, and outcomes of patients with SAB (clinical evaluable population)
Age, years, gender Source of infection Pathogen Days of IV
therapy
Agent Microbiological
response
Clinical
response
Telavancin, n = 8
55, male Peripherally inserted central catheter MRSA 15 Telavancin Eradication Cure
55, male Central IV catheter MRSA 14 Telavancin Eradication Cure
74, male Peripheral IV catheter MRSA 14 Telavancin Eradication Cure
37, male Central IV catheter MRSA 14 Telavancin Eradication Cure
53, male Cellulitis, associated with a previous
peripheral IV catheter
MSSA 12 Telavancin Eradication Cure
63, female Central IV catheter MRSA 13 Telavancin Eradication Cure
56, female Central IV catheter MSSA 15 Telavancin Eradication Cure
73, female Peripheral IV catheter MSSA 15 Telavancin Relapse Failure
Standard therapy, n = 9
25, female Cellulitis MRSA 15 Vancomycin Relapse Cure
59, male Peripheral IV catheter MRSA 14 Vancomycin Eradication Cure
87, female Peripherally inserted central catheter MSSA 14 Vancomycin Eradication Cure
75, male N/A MSSA 15 ASP Relapse Failure
55, female Peripherally inserted central catheter MSSA 15 Vancomycin Eradication Cure
83, female Decubitus ulcer MRSA 13 Vancomycin Eradication Cure
50, female Central IV catheter MSSA 15 ASP Eradication Cure
75, male Central IV catheter MSSA 15 ASP Eradication Cure
53, male Central IV catheter MRSA 13 Vancomycin Eradication Cure
ASP, anti-staphylococcal penicillin; IV, intravenous; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; N/A,
not available; SAB, Staphylococcus aureus bacteremia.
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While overall mortality of SAB in the pre-antibiotic
era was over 80% [24], death rates still remain high
(~30%) in contemporary series, particularly in patients
with complicated disease [2,25,26]. The relatively low
mortality found in this trial is consistent with both
adequate antimicrobial therapy and selection of patients
with uncomplicated disease.
Telavancin was tolerated in patients with uncomplicated
SAB. Although AEs were more common in patients receiv-
ing telavancin, AEs leading to drug discontinuation were
similar in the two groups. Consistent with a previously
reported study, increases in serum creatinine were more
common among telavancin-treated patients [27]. Changes
in serum creatinine appeared reversible when an adequate
FU was obtained and other contributing factors removed.
Apparent differences in mortality observed in the AT
population should be analyzed with caution. The apparent
higher mortality observed in the telavancin group may be
related to the small study size, and the fact that three died
after being withdrawn early due to complicated disease
and two died of other underlying conditions–urinary tract
infection/sepsis and prostate cancer.
Clinical identifiers of complications in patients with
SAB have been well described and include delayed clinical
and microbiological response to antibacterial therapy [2].
Despite these observations, identifying patients with
uncomplicated SAB at the initial evaluation is quite
challenging. For example, in a study that identified clinical
predictors of the presence of complicated S. aureus
bacteremia among 724 prospectively identified patients,
the risk for complications in patients with no identified
risk factors was still ~16%. Moreover, the most powerful
predictor of complicated S. aureus bacteremia, the pres-
ence of positive blood cultures at 48 to 96 h following the
initial BC, was by definition unavailable at the time
the patient was being considered for initial enrollment
into the study [2]. Our inability to accurately define
the extent of the disease at baseline in the present
Table 5 Safety parameters in the all-treated population
Telavancin Standard
therapy
(n = 29) (n = 29)
Deaths 5 (17%) 3 (10%)
Serious adverse events 11 (38%) 6 (21%)
Discontinuing study drug due to
an adverse event
2 (7%) 2 (7%)
≥1 adverse event 26 (90%) 21 (72%)
Adverse event ≥5% in any treatment arm
Pyrexia 4 (14%) 2 (7%)
Headache 3 (10%) 3 (10%)
Anemia 3 (10%) 2 (7%)
Rasha 2 (7%) 3 (10%)
Deep vein thrombosis 3 (10%) 1 (3%)
Hypokalemia 3 (10%) 1 (3%)
Nausea 1 (3%) 3 (10%)
Vomiting 1 (3%) 3 (10%)
Catheter site erythema 2 (7%) 1 (3%)
Dysgeusiab 3 (10%) 0
Agitation 2 (7%) 1 (3%)
Insomnia 2 (7%) 1 (3%)
Hematuria 1 (3%) 2 (7%)
Atelectasis 2 (7%) 1 (3%)
Dyspnea 1 (3%) 2 (7%)
Pruritus 1 (3%) 2 (7%)
Phlebitis 1 (3%) 2 (7%)
Urinary tract infectionc 4 (14%) 0
Acute renal failure 2 (7%) 0
Blood urea increased 2 (7%) 0
Eosinophiliad 0 4 (14%)
Diarrhea 0 2 (7%)
Catheter site infection 0 2 (7%)
aIncluding adverse events termed “rash,” “maculo-papular rash,” and
“rash pruritic.”
bUsually metallic taste.
cIncluding adverse events termed “urinary tract infection fungal” and “urinary
tract infection.”
dIncluding adverse events termed “eosinophilia” and “eosinophil
count increased.”
Table 6 Laboratory abnormalities in all-treated patients
with baseline normal valuesa
Telavancin Standard therapy
n/N n/N
Hematocrit
Male, ≤30% 1/4 (25%) 0/1 (0%)
Female, ≤28% 0/4 (0%) 0/3 (0%)
WBC ≤2800/μl 0/14 (0%) 0/15 (0%)
Platelet count ≤75,000/μl 0/18 (0%) 0/13 (0%)
AST (≥3 ULN) 3/18 (17%) 0/18 (0%)
ALT (≥3 ULN) 1/19 (5%) 1/17 (6%)
Alkaline phosphatase (≥1.5 ULN) 2/17 (12%) 1/22 (5%)
Potassium <3 meq/l 2/24 (8%) 0/19 (0%)
Potassium >5.5 meq/l 1/24 (4%) 3/19 (16%)
Creatinine increaseb 5/25 (20%) 2/28 (7%)
Baseline creatinine <1.5 mg/dl 4/18 (22%) 0/20 (0%)
Baseline creatinine ≥1.5 mg/dl 1/7 (14%) 2/8 (25%)
ALT, alanine aminotransferase; AST, aspartate aminotransferase, ULN, upper
limit of normal; WBC, white blood count.
aIncludes laboratory assessments after initiation of study drug up to and
including the earlier of the follow-up visit or 28 days after the last dose of
study medication.
bSerum creatinine ≥1.5 mg/dl and at least 50% greater than baseline; includes
patients with normal and abnormal values at baseline.
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study of uncomplicated SAB resulted in a significant
limitation in both enrollment and clinical evaluability.
This also highlights the significant unmet medical and
antimicrobial development need for rapid diagnostic
platforms that can reduce the time to identification
of the etiology and extent of bacterial bloodstream
infection.
This study has several important limitations. First, the
small study size limited the interpretation of outcome
data. Although a larger study would provide more
definitive evidence, the ASSURE trial provides proof-
of-concept that telavancin could potentially be an
effective therapy to treat patients with uncomplicated
SAB and warrants further study. Second, the diagnostic
techniques using blood cultures to determine bloodstream
infection are still far from ideal. Hopefully, in the future,
molecular techniques (e.g., polymerase chain reaction
[PCR]) for rapid determination of SAB and antibiotic
susceptibilities will be used in both clinical care and
in trials of new antimicrobial agents [28]. Third,
vancomycin was administered following local policies,
and as such, adjustment according to trough levels
was not mandatory. Although this fact may have re-
sulted in inadequate dosing (high or low), only one
patient with MRSA in the CE population experienced
a late relapse, suggesting that vancomycin dosing was
appropriate in most cases. There are also more recent
recommendations on vancomycin dosing that were
published after the start of this trial that will need to
be considered in future studies. Lastly, the exclusion
of patients with complicated disease resulted in a very
small population of evaluable patients. There was
also a possibility of underestimation of AEs due to
the small sample size. In the absence of data from
well-designed, adequately powered studies, physicians
will continue to treat patients suffering from this
life-threatening infection based on limited evidence
on antibiotic efficacy.
Conclusions
This study represents the first proof-of-concept for telavan-
cin in patients with uncomplicated SAB. Based on
these results, additional studies of telavancin in patients
with SAB, including complicated SAB, are warranted.
Endnote
aTelavancin is a lipoglycopeptide antibiotic approved
in the United States and Canada for the treatment of
patients with complicated skin and skin structure infections
due to susceptible Gram-positive pathogens, and in
the United States and Europe for the treatment of
hospital-acquired bacterial pneumonia, including ventilator-
associated bacterial pneumonia (HABP/VABP) due to
susceptible isolates of Staphylococcus aureus (methicillin-
resistant strains [MRSA] only in Europe), when alternative
medicines are unsuitable.
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